Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 10300152
Enzyme-encapsulated nanoparticle platform
granted -
US 10300106
Autophagy-inducing peptide analogs
granted -
US 10300043
Method for treating a gastrointestinal disorder in a mammal using bacteroides thetaiotaomicron and compositions thereof
granted -
US 10300073
Use of CDK9 and BRD4 inhibitors to inhibit inflammation
granted -
US 10300036
Compositions and methods for treating and preventing lung injury
granted -
US 10300117
Methods and compositions for improved cognition
granted -
US 10301626
Catalytic strands of minimal hammerhead ribozymes and methods of using the same
granted -
US 10292992
Selective high-affinity polydentate ligands and methods of making such
granted -
US 10293022
Peptide inhibitors of serotonin 5-HT2C receptor:PTEN interaction
granted -
US 10292986
Methods for treating epithelian mesenchymal transition related diseases
granted -
US 10293080
Ionic liquids that sterilize and prevent biofilm formation in skin wound healing devices
granted -
US 10293056
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
granted -
US 10293002
Methods and compositions for in vivo induction of pancreatic beta cell formation
granted -
US 10293012
Methods of using extracts of melissa officinalis against filoviruses
granted -
US 10293077
Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use
granted -
US 10287355
Methods and compositions for modulating lymphangiogenesis, E.G., to treat transplant rejection, in a subject
granted -
US 10287584
Compounds and methods for the modulation of COMP
granted -
US 10287334
Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain
granted -
US 10286016
Compositions and methods for treating gonorrhea
granted -
US 10286012
Compositions and methods for transplantation of colon microbiota
granted -
US 10286065
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
granted -
US 10285962
Glutarate compounds for treating ischemia-reperfusion injuries
granted -
US 10285996
Compositions comprising triterpenoids
granted -
US 10287312
Cyclic peroxides as prodrugs for selective delivery of agents
granted -
US 10285986
Compounds and anti-tumor NQO1 substrates
granted -
US 10286079
Modified cytotoxins and their therapeutic use
granted -
US 10285952
Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
granted -
US 10286011
Compositions and methods for transplantation of colon microbiota
granted -
US 10285988
Compounds for treatment of fibrosis diseases
granted -
US 10285940
Multicomponent, internally structured nanoemulsions and methods of production
granted -
US 10285945
Formation of stable submicron peptide or protein particles by thin film freezing
granted -
US 10287262
Eicosanoid derivatives
granted -
US 10287572
Protein scaffolds and methods of use
granted -
US 10285956
N-(2-aminoethyl) ethanolamine (AEEA) and analogs to treat hypertrophic scarring and liposomal topical delivery
granted -
US 10279042
One-step processing of hydrogels for mechanically robust and chemically desired features
granted -
US 10279023
Mucin-associated surface protein as a vaccine against chagas disease
granted -
US 10280171
Heterocyclic inhibitors of PTPN11
granted -
US 10280197
Discovery of the first selective C5A receptor 2 (C5L2/C5AR2) ligands
granted -
US 10279010
Methods and compositions for modulating myofibroblast activities
granted -
US 10279029
Immunogenic compositions and uses thereof
granted -
US 10280415
Human cystathionine Ξ²-synthase variants and methods of production thereof
granted -
US 10278982
Method of treating heterotopic ossification
granted -
US 10278986
Antibody-siRNA conjugates and uses therefor
granted -
US 10278372
Genetically modified cells, tissues, and organs for treating disease
granted -
US 10273333
Substituted polyesters by thiol-ene modification: rapid diversification for therapeutic protein stabilization
granted -
US 10272137
Compositions and methods relating to myomaker-induced muscle cell fusion
granted -
US 10272158
Compounds for treating biofilm infection
granted -
US 10273274
Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory